ENTA earnings date and last-quarter result: next report 2026-08-10, last quarter beat, P/E -4.77. Updated 2026-07-23.
Enanta Pharmaceuticals (ENTA) Research Hub
Enanta Pharmaceuticals (ENTA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 12 USD (+3.09%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.77, market cap 0.31B. This hub links to the full technical, earnings and options research available for ENTA.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 12 USD (+3.09%) |
| 52-week range | 10.94 USD – 15.51 USD |
| Trend regime | Range |
| 14-day RSI | 48.1 (Neutral) |
| Trailing P/E | -4.77 |
| Market cap | 0.31B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for ENTA
Covered Call on ENTA: how it works, illustrative setup around the real 12 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ENTA: how it works, illustrative setup around the real 12 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ENTA: how it works, illustrative setup around the real 12 USD price, max profit/loss, breakeven and when to use it. Educational.
ENTA technical analysis: range, last 12 USD, RSI 48.1, 52w range 10.94 USD–15.51 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ENTA in?
Enanta Pharmaceuticals (ENTA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ENTA in an uptrend or downtrend?
As of 2026-10-26, ENTA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ENTA's trailing P/E ratio?
ENTA's trailing P/E is -4.77, with a market cap of 0.31B. See the earnings research page for full valuation detail.
When does ENTA next report earnings?
ENTA is next scheduled to report earnings on 2026-08-10.